{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:07:47Z","timestamp":1792087667938,"version":"4.4.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s43440-025-00722-9","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T20:04:44Z","timestamp":1744142684000},"page":"561-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New pharmacological approaches in the treatment of schizophrenia"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7229-4747","authenticated-orcid":false,"given":"J\u00f3zef","family":"Muszy\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-5738","authenticated-orcid":false,"given":"Agnieszka","family":"Bienert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6424-105X","authenticated-orcid":false,"given":"Rasha Wafaie","family":"Elsorady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-3019","authenticated-orcid":false,"given":"Filip","family":"Rybakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"1","key":"722_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YPG.0000000000000245","volume":"30","author":"M Zamanpoor","year":"2020","unstructured":"Zamanpoor M. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet. 2020;30(1):1\u20139.","journal-title":"Psychiatr Genet"},{"issue":"12","key":"722_CR2","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, et al. Incidence, prevalence, and global burden of schizophrenia\u2014data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319\u201327.","journal-title":"Mol Psychiatry"},{"key":"722_CR3","unstructured":"Global Burden of Disease Study (GBD) Results. VizHub HealthData. 2019. Accesed 24 december 2024: https:\/\/vizhub.healthdata.org\/gbd-results\/?params=gbd-api-2019-permalink\/27a7644e8ad28e739382d31e77589dd7"},{"issue":"1","key":"722_CR4","doi-asserted-by":"publisher","first-page":"45094","DOI":"10.4088\/JCP.MS21078COM5","volume":"84","author":"DI Velligan","year":"2023","unstructured":"Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):45094.","journal-title":"J Clin Psychiatry"},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"789179","DOI":"10.3389\/fpsyt.2021.789179","volume":"12","author":"GM Giordano","year":"2021","unstructured":"Giordano GM, Bucci P, Mucci A, Pezzella P, Galderisi S. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review. Front Psychiatry. 2021;12:789179.","journal-title":"Front Psychiatry"},{"issue":"2","key":"722_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0020764019894608","volume":"66","author":"OO Fakorede","year":"2020","unstructured":"Fakorede OO, Ogunwale A, Akinhanmi AO. Disability among patients with schizophrenia: a hospital-based study. Int J Soc Psychiatry. 2020;66(2):179\u201387.","journal-title":"Int J Soc Psychiatry"},{"issue":"2","key":"722_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371.","journal-title":"World Psychiatry"},{"issue":"4","key":"722_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"C Hjorth\u00f8j","year":"2017","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295\u2013301.","journal-title":"Lancet Psychiatry"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"686666","DOI":"10.3389\/fgene.2021.686666","volume":"12","author":"N Robinson","year":"2021","unstructured":"Robinson N, Bergen SE. Environmental risk factors for schizophrenia and bipolar disorder and their relationship to genetic risk: current knowledge and future directions. Front Genet. 2021;12:686666.","journal-title":"Front Genet"},{"issue":"6","key":"722_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/archpsyc.1994.03950060020002","volume":"51","author":"KS Kendler","year":"1994","unstructured":"Kendler KS, Gruenberg AM, Kinney DK. Independent diagnoses of adoptees and relatives as defined by DSM-III in the provincial and National samples of the Danish adoption study of schizophrenia. Arch Gen Psychiatry. 1994;51(6):456\u201368.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"722_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/13651501.2017.1391292","volume":"22","author":"KN Fountoulakis","year":"2018","unstructured":"Fountoulakis KN, Gonda X, Siamouli M, Panagiotidis P, Moutou K, Nimatoudis I, et al. Paternal and maternal age as risk factors for schizophrenia: a case-control study. Int J Psychiatry Clin Pract. 2018;22(3):170\u20136.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"722_CR12","doi-asserted-by":"crossref","unstructured":"Uyan TT, Baltacioglu M, Hocaoglu C. Relationships between childhood trauma and dissociative, psychotic symptoms in patients with schizophrenia: A case-control study. Gen Psychiatry. 2022;35(1).","DOI":"10.1136\/gpsych-2021-100659"},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00406-019-01028-7","volume":"270","author":"J Henssler","year":"2020","unstructured":"Henssler J, Brandt L, M\u00fcller M, Liu S, Montag C, Sterzer P, Heinz A. Migration and schizophrenia: meta-analysis and explanatory framework. Eur Arch Psychiatry Clin Neurosci. 2020;270:325\u201335.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"722_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/schbul\/sbs096","volume":"38","author":"E Vassos","year":"2012","unstructured":"Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull. 2012;38(6):1118\u201323.","journal-title":"Schizophr Bull"},{"issue":"1","key":"722_CR15","doi-asserted-by":"publisher","first-page":"sgab056","DOI":"10.1093\/schizbullopen\/sgab056","volume":"3","author":"CB Pedersen","year":"2022","unstructured":"Pedersen CB, Antonsen S, Timmermann A, Pedersen MG, Ejlskov L, Horsdal HT, et al. Urban-rural differences in schizophrenia risk: multilevel survival analyses of individual- and neighborhood-level indicators, urbanicity, and population density in a Danish National cohort study. Schizophr Bull Open. 2022;3(1):sgab056.","journal-title":"Schizophr Bull Open"},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.schres.2019.10.012","volume":"216","author":"K Engemann","year":"2020","unstructured":"Engemann K, Svenning JC, Arge L, Brandt J, Geels C, Mortensen PB, et al. Natural surroundings in childhood are associated with lower schizophrenia rates. Schizophr Res. 2020;216:488\u201395.","journal-title":"Schizophr Res"},{"key":"722_CR17","doi-asserted-by":"crossref","unstructured":"Karlsson H, Dalman C. Epidemiological studies of prenatal and childhood infection and schizophrenia. Neuro Schizo. 2020:35\u201347.","DOI":"10.1007\/7854_2018_87"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.schres.2022.12.016","volume":"252","author":"SM Coury","year":"2023","unstructured":"Coury SM, Lombroso A, Avila-Quintero VJ, Taylor JH, Flores JM, Szejko N, et al. Systematic review and meta-analysis: season of birth and schizophrenia risk. Schizophr Res. 2023;252:244\u201352.","journal-title":"Schizophr Res"},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psychres.2018.11.023","volume":"271","author":"V Pugliese","year":"2019","unstructured":"Pugliese V, Bruni A, Carbone EA, Calabr\u00f2 G, Cerminara G, Sampogna G, et al. Maternal stress, prenatal medical illnesses, and obstetric complications: risk factors for schizophrenia spectrum disorder, bipolar disorder, and major depressive disorder. Psychiatry Res. 2019;271:23\u201330.","journal-title":"Psychiatry Res"},{"issue":"2","key":"722_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/oxfordjournals.schbul.a033452","volume":"26","author":"CA Schaefer","year":"2000","unstructured":"Schaefer CA, Brown AS, Wyatt RJ, Kline J, Begg MD, Bresnahan MA, et al. Maternal Prepregnant body mass and risk of schizophrenia in adult offspring. Schizophr Bull. 2000;26(2):275\u201386.","journal-title":"Schizophr Bull"},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.psychres.2015.12.026","volume":"236","author":"AM Fineberg","year":"2016","unstructured":"Fineberg AM, Ellman LM, Schaefer CA, Maxwell SD, Shen L, Chaudhury NH, et al. Fetal exposure to maternal stress and risk for schizophrenia spectrum disorders among offspring: differential influences of fetal sex. Psychiatry Res. 2016;236:91\u20137.","journal-title":"Psychiatry Res"},{"issue":"2","key":"722_CR22","first-page":"56","volume":"50","author":"I Urits","year":"2020","unstructured":"Urits I, Gress K, Charipova K, Li N, Berger AA, Cornett EM, et al. Cannabis use and its association with psychological disorders. Psychopharmacol Bull. 2020;50(2):56.","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"722_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","volume":"42","author":"A Marconi","year":"2016","unstructured":"Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262\u20139.","journal-title":"Schizophr Bull"},{"issue":"8","key":"722_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/brainsci13081193","volume":"13","author":"EM Tsapakis","year":"2023","unstructured":"Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel compounds in the treatment of schizophrenia\u2014a selective review. Brain Sci. 2023;13(8):1193.","journal-title":"Brain Sci"},{"issue":"5","key":"722_CR25","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41380-023-02043-w","volume":"28","author":"OD Howes","year":"2023","unstructured":"Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. Mol Psychiatry. 2023;28(5):1843\u201356.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"722_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","volume":"81","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9\u201320.","journal-title":"Biol Psychiatry"},{"key":"722_CR27","first-page":"2948","volume-title":"Chapter 67: schizophrenia","year":"2020","unstructured":"DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Crismon ML, Kattura RS, Buckley PF, editors. Chapter 67: schizophrenia. 11th ed. New York: McGraw-Hill; 2020. pp. 2948\u201391.","edition":"11"},{"issue":"1","key":"722_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","volume":"81","author":"JJ Weinstein","year":"2017","unstructured":"Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry. 2017;81(1):31\u201342.","journal-title":"Biol Psychiatry"},{"key":"722_CR29","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2147\/NDT.S118614","volume":"12","author":"H He","year":"2016","unstructured":"He H, Wu H, Yang L, Gao F, Fan Y, et al. Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis. Neuropsychiatr Dis Treat. 2016;12:3129\u201344.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"722_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S1092852918001013","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187\u201391.","journal-title":"CNS Spectr"},{"key":"722_CR31","volume-title":"Psychiatria: Podr\u0119cznik Dla Student\u00f3w Medycyny","year":"2016","unstructured":"Jarema M, editor. Psychiatria: Podr\u0119cznik Dla Student\u00f3w Medycyny. 2nd ed. Warszawa: PZWL; 2016.","edition":"2"},{"issue":"5","key":"722_CR32","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RS, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28(5):1902\u201318.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"722_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881120944156","volume":"35","author":"AJ Loonen","year":"2021","unstructured":"Loonen AJ, Ivanova SA. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. J Psychopharmacol. 2021;35(1):3\u201314.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"722_CR34","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/cells10102679","volume":"10","author":"KT Thomas","year":"2021","unstructured":"Thomas KT, Zakharenko SS. MicroRNAs in the onset of schizophrenia. Cells. 2021;10(10):2679.","journal-title":"Cells"},{"issue":"1","key":"722_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.12.022","volume":"117","author":"I Ellison-Wright","year":"2010","unstructured":"Ellison-Wright I, Bullmore ED. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr Res. 2010;117(1):1\u20132.","journal-title":"Schizophr Res"},{"issue":"3","key":"722_CR36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/schbul\/sbr030","volume":"37","author":"N Gogtay","year":"2011","unstructured":"Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull. 2011;37(3):504\u201313.","journal-title":"Schizophr Bull"},{"issue":"3","key":"722_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/schbul\/sbp131","volume":"37","author":"J Camchong","year":"2011","unstructured":"Camchong J, MacDonald AW III, Bell C, Mueller BA, Lim KO. Altered functional and anatomical connectivity in schizophrenia. Schizophr Bull. 2011;37(3):640\u201350.","journal-title":"Schizophr Bull"},{"issue":"9","key":"722_CR38","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Pharm Ther. 2014;39(9):638.","journal-title":"Pharm Ther"},{"issue":"3","key":"722_CR39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.12740\/PP\/OnlineFirst\/100698","volume":"53","author":"J Heitzman","year":"2019","unstructured":"Heitzman J, Dudek D. Recommendations for the treatment of schizophrenia with negative symptoms. Psychiatr Pol. 2019;53(3):497\u2013524.","journal-title":"Psychiatr Pol"},{"issue":"8","key":"722_CR40","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/NMD.0b013e318225ee78","volume":"199","author":"FB Dickerson","year":"2011","unstructured":"Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis. 2011;199(8):520\u20136.","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"722_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstr\u00f6m O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"8","key":"722_CR42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","volume":"40","author":"M Valenstein","year":"2002","unstructured":"Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630\u20139.","journal-title":"Med Care"},{"issue":"2","key":"722_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.psychres.2007.07.012","volume":"161","author":"PM Llorca","year":"2008","unstructured":"Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161(2):235\u201347.","journal-title":"Psychiatry Res"},{"key":"722_CR44","first-page":"145","volume":"11","author":"A Caqueo-Ur\u00edzar","year":"2015","unstructured":"Caqueo-Ur\u00edzar A, Rus-Calafell M, Urz\u00faa A, Escudero J, Guti\u00e9rrez-Maldonado J. The role of family therapy in the management of schizophrenia: challenges and solutions. Neuropsychiatr Dis Treat. 2015;11:145\u201351.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"722_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","volume":"386","author":"RT Espinoza","year":"2022","unstructured":"Espinoza RT, Kellner CH. Electroconvulsive therapy. N Engl J Med. 2022;386(7):667\u201372.","journal-title":"N Engl J Med"},{"key":"722_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jpsychires.2018.08.002","volume":"105","author":"G Wang","year":"2018","unstructured":"Wang G, Zheng W, Li XB, Wang SB, Cai DB, Yang XH, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;105:23\u201332.","journal-title":"J Psychiatr Res"},{"key":"722_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.psychres.2018.12.143","volume":"272","author":"MZ Li","year":"2019","unstructured":"Li MZ, Chen LC, Rong H, Xu SX, Li Y, Yang QF, et al. Low-charge electrotherapy for patients with schizophrenia: a double-blind, randomised controlled pilot clinical trial. Psychiatry Res. 2019;272:676\u201381.","journal-title":"Psychiatry Res"},{"issue":"6","key":"722_CR48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1192\/bjp.bp.110.077289","volume":"197","author":"AB Staring","year":"2010","unstructured":"Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197(6):448\u201355.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"722_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"key":"722_CR50","doi-asserted-by":"crossref","unstructured":"Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. Chichester: Wiley; 2021 Jul;13.","DOI":"10.1002\/9781119870203"},{"key":"722_CR51","doi-asserted-by":"crossref","unstructured":"Ameer MA, Patel P, Saadabadi A. Neuroleptic medications. StatPearls [Internet]. StatPearls Publishing; 2024 Feb 21.","DOI":"10.1080\/15424065.2024.2389325"},{"issue":"2","key":"722_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5603\/ppn.100001","volume":"20","author":"J S\u0142awek","year":"2024","unstructured":"S\u0142awek J, Bia\u0142ecka M, Dudek D, Koziorowski D, Rudzi\u0144ska-Bar M. P\u00f3\u017ane dyskinezy polekowe\u2014rekomendacje grupy Ekspert\u00f3w: Aktualizacja 2024. Pol Przegl Neurol. 2024;20(2):59\u201370.","journal-title":"Pol Przegl Neurol"},{"issue":"3","key":"722_CR53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.12740\/PP\/OnlineFirst\/100698","volume":"53","author":"A Szulc","year":"2019","unstructured":"Szulc A, Samochowiec J, Ga\u0142ecki P, Wojnar M, Heitzman J, Dudek D. Rekomendacje Dotycz\u0105ce Leczenia schizofrenii Z Objawami Negatywnymi: standardy Farmakoterapii Polskiego Towarzystwa Psychiatrycznego, Cz\u0119\u015b\u0107 1. Psychiatr Pol. 2019;53(3):497\u2013524.","journal-title":"Psychiatr Pol"},{"key":"722_CR54","doi-asserted-by":"crossref","unstructured":"Freudenreich O. Psychotic Disorders. In: Current Clinical Psychiatry. 2020.","DOI":"10.1007\/978-3-030-29450-2"},{"issue":"5","key":"722_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/2042098618756261","volume":"9","author":"D De Berardis","year":"2018","unstructured":"De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9(5):237\u201356.","journal-title":"Ther Adv Drug Saf"},{"key":"722_CR56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-7091-1501-5_6","volume-title":"Psychiatric drugs in children and adolescents: basic Pharmacology and practical applications","author":"M Gerlach","year":"2014","unstructured":"Gerlach M, Warnke A. Anxiolytics and Sedative-Hypnotics. Psychiatric drugs in children and adolescents: Basic pharmacology and practical applications. Vienna: Springer Vienna; 2014 Feb 26:219\u201355."},{"key":"722_CR57","doi-asserted-by":"crossref","unstructured":"Howes OD, Dawkins E, Lobo MC, Kaar SJ, Beck K. New drug treatments for schizophrenia: A review of approaches to target circuit dysfunction. Biol Psychiatry. 2024 May 28.","DOI":"10.1016\/j.biopsych.2024.05.014"},{"issue":"2","key":"722_CR58","first-page":"77","volume":"15","author":"P Bie\u0144kowski","year":"2018","unstructured":"Bie\u0144kowski P. Kariprazyna\u2014lek Przeciwpsychotyczny O profilu Cz\u0119\u015bciowego agonisty Receptor\u00f3w Dopaminowych. Psychiatria. 2018;15(2):77\u201381.","journal-title":"Psychiatria"},{"key":"722_CR59","unstructured":"Richter Gedeon Nyrt. Richter.hu. Published 2025. Accessed February 12. 2025. Available from: http:\/\/www.richter.hu\/en-US\/investors\/announcements\/Pages\/07-19.aspx"},{"issue":"4","key":"722_CR60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","volume":"35","author":"JM Kane","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of Cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367\u201373.","journal-title":"J Clin Psychopharmacol"},{"issue":"2\u20133","key":"722_CR61","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","volume":"176","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term Cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2\u20133):264\u201371.","journal-title":"Schizophr Res"},{"issue":"4","key":"722_CR62","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/appi.focus.18306","volume":"18","author":"M Huhn","year":"2020","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Focus. 2020;18(4):443\u201355.","journal-title":"Focus"},{"key":"722_CR63","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/NDT.S301225","volume":"17","author":"\u00c1 Barab\u00e1ssy","year":"2021","unstructured":"Barab\u00e1ssy \u00c1, Sebe B, Acsai K, Laszlovszky I, Szatm\u00e1ri B, Earley WR, et al. Safety and tolerability of Cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies. Neuropsychiatr Dis Treat. 2021;17:957\u201370.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"722_CR64","first-page":"1","volume":"73","author":"A Rutecka","year":"2017","unstructured":"Rutecka A, Ciura K, Nowakowska J. Brekspiprazol\u2013 nadzieja W Leczeniu schizofrenii. Farm Pol. 2017;73(1):1\u20137.","journal-title":"Farm Pol"},{"key":"722_CR65","unstructured":"News FDA. Issue 1\u20134, January 2022. ASCPT. Published 2022. Available from: https:\/\/www.ascpt.org\/Resources\/ASCPT-News\/View\/ArticleId\/27576\/FDA-News-Issue-1-4-January-2022. Accessed 12 Feb 2025."},{"issue":"2","key":"722_CR66","first-page":"107","volume":"38","author":"K Bogusz","year":"2022","unstructured":"Bogusz K, Wojnar M. Brexpiprazole in the treatment of schizophrenia: pharmacology, efficacy, and side effects profile. Pharmakoter Psychiatr Neurol. 2022;38(2):107\u201318.","journal-title":"Pharmakoter Psychiatr Neurol"},{"issue":"1\u20133","key":"722_CR67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","volume":"174","author":"CU Correll","year":"2016","unstructured":"Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Efficacy of Brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1\u20133):82\u201392.","journal-title":"Schizophr Res"},{"issue":"1","key":"722_CR68","first-page":"11","volume":"20","author":"WW Fleischhacker","year":"2017","unstructured":"Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, et al. Efficacy and safety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"key":"722_CR69","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00213-020-05472-5","volume":"237","author":"T Kishi","year":"2020","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Iwata N. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology. 2020;237:1459\u201370.","journal-title":"Psychopharmacology"},{"issue":"24","key":"722_CR70","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185.","journal-title":"Int J Mol Sci"},{"key":"722_CR71","unstructured":"Sumitomo Pharma and Otsuka. Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia. [Internet]. Princeton (NJ): Otsuka US; 2023 Jul 31. Available from: https:\/\/otsuka-us.com\/news\/sumitomo-pharma-and-otsuka-announce-topline-results-phase-3-diamond-1-and-diamond-2-clinical"},{"issue":"7","key":"722_CR72","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1543\u201356.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"722_CR73","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/NDT.S501560","volume":"20","author":"M Luca","year":"2024","unstructured":"Luca M, Luca A, Serretti A. A clinically oriented review of new antipsychotics for schizophrenia. Neuropsychiatr Dis Treat. 2024;20:2637\u201349.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"722_CR74","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40263-021-00864-3","volume":"35","author":"JT Kantrowitz","year":"2021","unstructured":"Kantrowitz JT. Trace amine-associated receptor 1 as a target for the development of new antipsychotics: current status of research and future directions. CNS Drugs. 2021;35(11):1153\u201361.","journal-title":"CNS Drugs"},{"issue":"9","key":"722_CR75","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ijnp\/pyad049","volume":"26","author":"R Agren","year":"2023","unstructured":"Agren R, Betari N, Saarinen M, Zeberg H, Svenningsson P, Sahlholm K. In vitro comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): two TAAR1 agonist candidate antipsychotics. Int J Neuropsychopharmacol. 2023;26(9):599\u2013606.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"722_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll CU, Koblan KS, Hopkins SC, Li Y, Dworak H, Goldman R, Loebel A. Safety and effectiveness of Ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. Npj Schizophrenia. 2021;7(1):63.","journal-title":"Npj Schizophrenia"},{"key":"722_CR77","doi-asserted-by":"crossref","unstructured":"Siafis S, Chiocchia V, Macleod MR, Austin C, Homiar A, Tinsdeall F, et al. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data. Wellcome Open Res. 2024;9.","DOI":"10.12688\/wellcomeopenres.21302.1"},{"issue":"4","key":"722_CR78","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41380-018-0104-7","volume":"25","author":"J Kumar","year":"2020","unstructured":"Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry. 2020;25(4):873\u201382.","journal-title":"Mol Psychiatry"},{"key":"722_CR79","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neulet.2016.10.006","volume":"634","author":"SE Cho","year":"2016","unstructured":"Cho SE, Na KS, Cho SJ, Kang SG. Low d-serine levels in schizophrenia: A systematic review and meta-analysis. Neurosci Lett. 2016;634:42\u201351.","journal-title":"Neurosci Lett"},{"issue":"1\u20133","key":"722_CR80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121(1\u20133):125\u201330.","journal-title":"Schizophr Res"},{"key":"722_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2017.02.027","volume":"191","author":"JT Kantrowitz","year":"2018","unstructured":"Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70\u20139.","journal-title":"Schizophr Res"},{"issue":"1","key":"722_CR82","first-page":"859735","volume":"2014","author":"AR Durrant","year":"2014","unstructured":"Durrant AR, Heresco-Levy U. D-Serine in neuropsychiatric disorders: new advances. Adv Psychiatry. 2014;2014(1):859735.","journal-title":"Adv Psychiatry"},{"key":"722_CR83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fpsyt.2019.00025","volume":"10","author":"MA MacKay","year":"2019","unstructured":"MacKay MA, Kravtsenyuk M, Thomas R, Mitchell ND, Dursun SM, Baker GB. D-Serine: potential therapeutic agent and\/or biomarker in schizophrenia and depression? Front Psychiatry. 2019;10:25.","journal-title":"Front Psychiatry"},{"key":"722_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.apha.2016.02.001","volume":"39","author":"D Goff","year":"2016","unstructured":"Goff D. The therapeutic role of d-Cycloserine in schizophrenia. Adv Pharmacol. 2016;39:39\u201366.","journal-title":"Adv Pharmacol"},{"key":"722_CR85","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00702-020-02292-x","volume":"128","author":"PP Kuppili","year":"2021","unstructured":"Kuppili PP, Menon V, Sathyanarayanan G, Sarkar S, Andrade C. Efficacy of adjunctive D-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. J Neural Transm (Vienna). 2021;128:253\u201362.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1\u20133","key":"722_CR86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.schres.2011.05.029","volume":"131","author":"JD Gottlieb","year":"2011","unstructured":"Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res. 2011;131(1\u20133):69\u201374.","journal-title":"Schizophr Res"},{"issue":"4","key":"722_CR87","doi-asserted-by":"publisher","first-page":"pyv102","DOI":"10.1093\/ijnp\/pyv102","volume":"19","author":"S Schade","year":"2016","unstructured":"Schade S, Paulus W. D-cycloserine in neuropsychiatric diseases: a systematic review. Int J Neuropsychopharmacol. 2016;19(4):pyv102.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"722_CR88","first-page":"1311","volume":"19","author":"P Chue","year":"2013","unstructured":"Chue P. Glycine reuptake Inhibition as a new therapeutic approach in schizophrenia: focus on the Glycine transporter 1 (GlyT1). Curr Pharm Des. 2013;19(7):1311\u201320.","journal-title":"Curr Pharm Des"},{"issue":"19","key":"722_CR89","doi-asserted-by":"publisher","first-page":"10668","DOI":"10.3390\/ijms251910668","volume":"25","author":"T Zhang","year":"2024","unstructured":"Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X. Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways. Int J Mol Sci. 2024;25(19):10668.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"722_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881120908016","volume":"34","author":"CH Chang","year":"2020","unstructured":"Chang CH, Lin CH, Liu CY, Chen SJ, Lane HY. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol. 2020;34(5):495\u2013505.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"722_CR91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17425255.2021.1885648","volume":"17","author":"M Marchi","year":"2021","unstructured":"Marchi M, Galli G, Magarini FM, Mattei G, Galeazzi GM. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Metab Toxicol. 2021;17(4):483\u201393.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"722_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, et al. Bitopertin in negative symptoms of schizophrenia\u2014results from the phase III flashlyte and daylyte studies. Biol Psychiatry. 2017;82(1):8\u201316.","journal-title":"Biol Psychiatry"},{"issue":"12","key":"722_CR93","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"D Bugarski-Kirola","year":"2016","unstructured":"Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, et al. Efficacy and safety of adjunctive Bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the searchlyte clinical trial programme. Lancet Psychiatry. 2016;3(12):1115\u201328.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"722_CR94","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, Iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1557\u201366.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"722_CR95","doi-asserted-by":"crossref","unstructured":"Komatsu Y, Takehara M, Hart X, Takahashi Y, Hori S, Ueno F et al. Advancements in Non-Dopaminergic treatments for schizophrenia: A systematic review of pipeline developments. Pharmacopsychiatry. 2024 May 6.","DOI":"10.1055\/a-2307-6484"},{"key":"722_CR96","unstructured":"Boehringer Ingelheim. Update on the Phase III CONNEX clinical program in schizophrenia. [Internet]. Ingelheim am Rhein: Boehringer Ingelheim. 2025. Available from: https:\/\/www.boehringer-ingelheim.com\/human-health\/mental-health\/schizophrenia\/update-phase-iii-connex-clinical-program-schizophrenia"},{"issue":"4","key":"722_CR97","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4155\/fmc.15.4","volume":"7","author":"SE Ward","year":"2015","unstructured":"Ward SE, Pennicott LE, Beswick P. AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications. Future Med Chem. 2015;7(4):473\u201391.","journal-title":"Future Med Chem"},{"issue":"1","key":"722_CR98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41398-024-03194-2","volume":"15","author":"D Olivares-Berjaga","year":"2025","unstructured":"Olivares-Berjaga D, Mart\u00ednez-Pinte\u00f1o A, Rodr\u00edguez N, Mas S, Mor\u00e9n C, Parellada E, et al. Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2\/3 (mGluR2\/3) in animal models of schizophrenia. Transl Psychiatry. 2025;15(1):11.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"722_CR99","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1002\/prp2.479","volume":"7","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Kunugi A, Suzuki A, Suzuki N, Suzuki M, Kimura H. Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia. Pharmacol Res Perspect. 2019;7(3):e00479.","journal-title":"Pharmacol Res Perspect"},{"key":"722_CR100","unstructured":"Tanaka M. In Vivo Studies on the Regulation of Neuropsychiatric Behaviors via CRF and AMPA Receptor Signaling. Doctoral dissertation, University of Tsukuba, 2020."},{"issue":"11","key":"722_CR101","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40263-022-00959-5","volume":"36","author":"CY Kuo","year":"2022","unstructured":"Kuo CY, Lin CH, Lane HY. Targeting D-amino acid oxidase (DAAO) for the treatment of schizophrenia: rationale and current status of research. CNS Drugs. 2022;36(11):1143\u201353.","journal-title":"CNS Drugs"},{"issue":"1","key":"722_CR102","doi-asserted-by":"publisher","first-page":"pyae066","DOI":"10.1093\/ijnp\/pyae066","volume":"28","author":"RT Terry-Lorenzo","year":"2025","unstructured":"Terry-Lorenzo RT, Fan RH, Khin NA, Singh JB. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. Int J Neuropsychopharmacol. 2025;28(1):pyae066.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"722_CR103","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","volume":"70","author":"HY Lane","year":"2013","unstructured":"Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12):1267\u201375.","journal-title":"JAMA Psychiatry"},{"key":"722_CR104","doi-asserted-by":"publisher","first-page":"1370431","DOI":"10.3389\/fpsyt.2024.1370431","volume":"15","author":"CW Liang","year":"2024","unstructured":"Liang CW, Cheng HY, Tseng MC. Effects of sodium benzoate on cognitive function in neuropsychiatric disorders: a systematic review and meta-analysis. Front Psychiatry. 2024;15:1370431.","journal-title":"Front Psychiatry"},{"key":"722_CR105","doi-asserted-by":"crossref","unstructured":"Victor R, Avinash P, Singhania R. Effect of sodium benzoate as an Add-on therapy on the clinical and cognitive symptoms of schizophrenia: A case series. J Clin Diagn Res. 2024;18(6).","DOI":"10.7860\/JCDR\/2024\/69905.19492"},{"key":"722_CR106","doi-asserted-by":"publisher","first-page":"102947","DOI":"10.1016\/j.ajp.2021.102947","volume":"68","author":"JC Seetharam","year":"2022","unstructured":"Seetharam JC, Maiti R, Mishra A, Mishra BR. Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: A systematic review and meta-analysis. Asian J Psychiatr. 2022;68:102947.","journal-title":"Asian J Psychiatr"},{"issue":"2","key":"722_CR107","first-page":"21","volume":"11","author":"GS Mahmoud","year":"2019","unstructured":"Mahmoud GS, Sayed SA, Abdelmawla SN, Amer MA. Positive effects of systemic sodium benzoate and olanzapine treatment on activities of daily life, Spatial learning and working memory in ketamine-induced rat model of schizophrenia. Int J Physiol Pathophysiol Pharmacol. 2019;11(2):21.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"722_CR108","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/NDT.S455279","volume":"31","author":"A Peng","year":"2024","unstructured":"Peng A, Chai J, Wu H, Bai B, Yang H, He W, et al. New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat. 2024;31:607\u201320.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"722_CR109","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/cmdc.201500437","volume":"10","author":"J Cheng","year":"2015","unstructured":"Cheng J, Kozikowski AP. We need 2\u00a0C but not 2B: developing serotonin 2\u00a0C (5-HT2C) receptor agonists for the treatment of CNS disorders. ChemMedChem. 2015;10(12):1963\u20137.","journal-title":"ChemMedChem"},{"issue":"3","key":"722_CR110","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/1871527322666230330124137","volume":"23","author":"M Mazza","year":"2024","unstructured":"Mazza M, Kotzalidis GD, Marano G, De Berardis D, Martinotti G, Romagnoli E, et al. Lorcaserin: worthy of further insights? Results from recent research. CNS Neurol Disord Drug Targets. 2024;23(3):278\u201383.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"722_CR111","doi-asserted-by":"crossref","unstructured":"Capuzzi E, Caldiroli A, Ciscato V, Russo S, Buoli M. Experimental serotonergic agents for the treatment of schizophrenia. J Exp Pharmacol. 2021:49\u201367.","DOI":"10.2147\/JEP.S259317"},{"key":"722_CR112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","volume":"113","author":"W Zheng","year":"2019","unstructured":"Zheng W, Cai DB, Zhang QE, He J, Zhong LY, Sim K, et al. Adjunctive Ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019;113:27\u201333.","journal-title":"J Psychiatr Res"},{"key":"722_CR113","doi-asserted-by":"crossref","unstructured":"Dudzik P, Lustyk K, Pytka K. Beyond dopamine: Novel strategies for schizophrenia treatment. Med Res Rev. 2024;23.","DOI":"10.1002\/med.22042"},{"key":"722_CR114","unstructured":"U.S. Food and Drug Administration. FDA approves drug with new mechanism of action for treatment of schizophrenia. [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia"},{"key":"722_CR115","doi-asserted-by":"crossref","unstructured":"Azargoonjahromi A. Current findings and potential mechanisms of KarXT (Xanomeline\u2013Trospium) in schizophrenia treatment. Clin Drug Investig. 2024:1\u201323.","DOI":"10.1007\/s40261-024-01377-9"},{"issue":"6","key":"722_CR116","first-page":"624","volume":"30","author":"A McKenna","year":"2024","unstructured":"McKenna A, Tice JA, Whittington MD, Wright AC, Richardson M, Raymond FR, et al. KarXT for schizophrenia\u2013effectiveness and value: A summary from the Institute for clinical and economic review\u2019s new England comparative effectiveness public advisory Council. J Manag Care Spec Pharm. 2024;30(6):624\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"722_CR117","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","volume":"274","author":"AC Wright","year":"2024","unstructured":"Wright AC, McKenna A, Tice JA, Rind DM, Agboola F. A network meta-analysis of KarXT and commonly used Pharmacological interventions for schizophrenia. Schizophr Res. 2024;274:212\u20139.","journal-title":"Schizophr Res"},{"issue":"10369","key":"722_CR118","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400(10369):2210\u201320.","journal-title":"Lancet"},{"issue":"1","key":"722_CR119","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1021\/acsmedchemlett.6b00514","volume":"8","author":"AF Abdel-Magid","year":"2017","unstructured":"Abdel-Magid AF. Potential treatment of cognitive impairment in schizophrenia by phosphodiesterase 2 (PDE2) inhibitors. ACS Med Chem Lett. 2017;8(1):17\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"722_CR120","doi-asserted-by":"crossref","unstructured":"Snyder GL, Vanover KE. PDE Inhibitors for the Treatment of Schizophrenia. In: Phosphodiesterases: CNS Functions and Diseases. 2017:385\u2013409.","DOI":"10.1007\/978-3-319-58811-7_14"},{"issue":"1","key":"722_CR121","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0269881120946300","volume":"35","author":"J Gilleen","year":"2021","unstructured":"Gilleen J, Nottage J, Yakub F, Kerins S, Valdearenas L, Uz T, et al. The effects of Roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial. J Psychopharmacol. 2021;35(1):15\u201322.","journal-title":"J Psychopharmacol"},{"key":"722_CR122","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00213-018-5134-y","volume":"238","author":"J Gilleen","year":"2021","unstructured":"Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, et al. An experimental medicine study of the phosphodiesterase-4 inhibitor, Roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology. 2021;238:1279\u201389.","journal-title":"Psychopharmacology"},{"issue":"2","key":"722_CR123","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/schbul\/sby049","volume":"45","author":"D Brown","year":"2019","unstructured":"Brown D, Nakagome K, Cordes J, Brenner R, Gr\u00fcnder G, Keefe RS, et al. Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial. Schizophr Bull. 2019;45(2):350\u20139.","journal-title":"Schizophr Bull"},{"issue":"6","key":"722_CR124","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/JCP.0000000000001128","volume":"39","author":"DP Walling","year":"2019","unstructured":"Walling DP, Banerjee A, Dawra V, Boyer S, Schmidt CJ, DeMartinis N. Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia. J Clin Psychopharmacol. 2019;39(6):575\u201382.","journal-title":"J Clin Psychopharmacol"},{"key":"722_CR125","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","volume":"270","author":"Y Mukai","year":"2024","unstructured":"Mukai Y, Lupinacci R, Marder S, Snow-Adami L, Voss T, Smith SM, et al. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophr Res. 2024;270:37\u201343.","journal-title":"Schizophr Res"},{"key":"722_CR126","doi-asserted-by":"publisher","first-page":"1057083","DOI":"10.3389\/fphar.2022.1057083","volume":"13","author":"AD Bondarev","year":"2022","unstructured":"Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Liu W, et al. Recent developments of phosphodiesterase inhibitors: clinical trials, emerging indications and novel molecules. Front Pharmacol. 2022;13:1057083.","journal-title":"Front Pharmacol"},{"issue":"6","key":"722_CR127","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/13543784.2023.2219385","volume":"32","author":"M Musselman","year":"2023","unstructured":"Musselman M, Huynh E, Kelshikar R, Lee E, Malik M, Faden J. Potassium channel modulators and schizophrenia: an overview of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):471\u20137.","journal-title":"Expert Opin Investig Drugs"},{"issue":"16","key":"722_CR128","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.3390\/ijms25168696","volume":"25","author":"M Yanagi","year":"2024","unstructured":"Yanagi M, Hashimoto M. Dysfunctional parvalbumin neurons in schizophrenia and the pathway to the clinical application of Kv3 channel modulators. Int J Mol Sci. 2024;25(16):8696.","journal-title":"Int J Mol Sci"},{"key":"722_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13229-020-00357-y","volume":"11","author":"RA Seymour","year":"2020","unstructured":"Seymour RA, Rippon G, Gooding-Williams G, Sowman PF, Kessler K. Reduced auditory steady state responses in autism spectrum disorder. Mol Autism. 2020;11:1\u20133.","journal-title":"Mol Autism"},{"issue":"9","key":"722_CR130","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/02698811221122031","volume":"36","author":"I Angelescu","year":"2022","unstructured":"Angelescu I, Kaar SJ, Marques TR, Borgan F, Veronesse M, Sharman A, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. J Psychopharmacol. 2022;36(9):1061\u20139.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"722_CR131","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/15500594221148643","volume":"55","author":"SJ Kaar","year":"2024","unstructured":"Kaar SJ, Nottage JF, Angelescu I, Marques TR, Howes OD. Gamma oscillations and potassium channel modulation in schizophrenia: targeting GABAergic dysfunction. Clin EEG Neurosci. 2024;55(2):203\u201313.","journal-title":"Clin EEG Neurosci"},{"key":"722_CR132","doi-asserted-by":"publisher","first-page":"239821282110091","DOI":"10.1177\/23982128211009148","volume":"5","author":"T Notter","year":"2021","unstructured":"Notter T. Astrocytes in schizophrenia. Brain Neurosci Adv. 2021;5:23982128211009148.","journal-title":"Brain Neurosci Adv"},{"issue":"14","key":"722_CR133","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.3390\/jcm11143964","volume":"11","author":"B Gali\u0144ska-Skok","year":"2022","unstructured":"Gali\u0144ska-Skok B, Waszkiewicz N. Markers of schizophrenia\u2014a critical narrative update. J Clin Med. 2022;11(14):3964.","journal-title":"J Clin Med"},{"key":"722_CR134","doi-asserted-by":"publisher","first-page":"100118","DOI":"10.1016\/j.pmip.2024.100118","volume":"43","author":"AJ Nashwan","year":"2024","unstructured":"Nashwan AJ, Elawfi B. Beyond one-size-fits-all: the rise of personalized treatment in schizophrenia. Personalized Med Psychiatry. 2024;43:100118.","journal-title":"Personalized Med Psychiatry"},{"issue":"6","key":"722_CR135","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0013-7006(19)30077-6","volume":"44","author":"F Gaillard-Bigot","year":"2018","unstructured":"Gaillard-Bigot F, Zendjidjian XY, Kheloufi F, Casse-Perrot C, Guilhaumou R, Micallef J, et al. Quantitative system Pharmacology (QSP): an integrative framework for paradigm change in the treatment of the first-episode schizophrenia. L\u2019encephale. 2018;44(6):S34\u20138.","journal-title":"L\u2019encephale"},{"issue":"1","key":"722_CR136","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41537-025-00583-4","volume":"11","author":"S Jiang","year":"2025","unstructured":"Jiang S, Jia Q, Peng Z, Zhou Q, An Z, Chen J, et al. Can artificial intelligence be the future solution to the enormous challenges and suffering caused by schizophrenia?? Schizophrenia. 2025;11(1):32.","journal-title":"Schizophrenia"},{"key":"722_CR137","unstructured":"National Institutes of Health (NIH). D-serine adjunctive therapy for cognitive impairment in schizophrenia (NCT05046353). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05046353"},{"key":"722_CR138","unstructured":"National Institutes of Health (NIH). D-cycloserine to Augment Cognitive Remediation in Schizophrenia. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00964041?intr=D-cycloserine%20schizophrenia&rank=4"},{"key":"722_CR139","unstructured":"National Taiwan University Hospital. Sarcosine Treatment for Schizophrenia. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01503359?intr=sarcosine%20schizophrenia&rank=1"},{"key":"722_CR140","unstructured":"National Institutes of Health (NIH). Sodium benzoate adjunctive therapy for schizophrenia (NCT01908192). Available from: https:\/\/clinicaltrials.gov\/study\/NCT01908192"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00722-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00722-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00722-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:03:57Z","timestamp":1747058637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00722-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":140,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00722-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}